- Email: [email protected]
Personalized Medicine in Endocrine Therapy for Breast Cancer Based on the Type of Resistant Mechanism
Annals of Oncology 25 (Supplement 5): v12, 2014 doi:10.1093/annonc/mdu405.3
JSMO/JBCS Joint Symposium (JS4): ‘Development of breast cancer individual treatment’ 4
PERSONALIZED MEDICINE IN ENDOCRINE THERAPY FOR BREAST CANCER BASED ON THE TYPE OF RESISTANT MECHANISM
abstracts
Shigehira Saji Target Therapy Oncology, Kyoto University Graduate School of Medicine
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v12/2240135 by guest on 25 October 2019
JS4
Endocrine therapy was most widely used modality for breast cancer patients. Basically, expression of either Estrogen Receptor (ER) or Progesterone Receptor (PR) predicts the response to therapy, its positive predictive value seems to be around 50-60%. In addition, so called “acquired resistance (secondary resistance)”, which is the development of resistance during long-term single endocrine therapy, has been important research issue. Simultaneous use of molecular targeting dug such as mTOR inhibitor or PI3K pathway inhibitor with second endocrine therapy could be important strategy for this acquired resistance. Although at this moment there is no companion assay for evaluating the molecular mechanism of acquired resistance in real time manner, we try to imagine the type of resistance from patient treatment history. Obviously the assay for this purpose should be urgent research target probably developed with liquid biopsy. In this session, we would review the current understanding of primary and secondary resistance, and try to figure out the way for personalized medicine in endocrine therapy.
JSMO/JBCS Joint Symposium (JS4): ‘Development of breast cancer individual treatment’ 4
PERSONALIZED MEDICINE IN ENDOCRINE THERAPY FOR BREAST CANCER BASED ON THE TYPE OF RESISTANT MECHANISM
abstracts
Shigehira Saji Target Therapy Oncology, Kyoto University Graduate School of Medicine
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v12/2240135 by guest on 25 October 2019
JS4
Endocrine therapy was most widely used modality for breast cancer patients. Basically, expression of either Estrogen Receptor (ER) or Progesterone Receptor (PR) predicts the response to therapy, its positive predictive value seems to be around 50-60%. In addition, so called “acquired resistance (secondary resistance)”, which is the development of resistance during long-term single endocrine therapy, has been important research issue. Simultaneous use of molecular targeting dug such as mTOR inhibitor or PI3K pathway inhibitor with second endocrine therapy could be important strategy for this acquired resistance. Although at this moment there is no companion assay for evaluating the molecular mechanism of acquired resistance in real time manner, we try to imagine the type of resistance from patient treatment history. Obviously the assay for this purpose should be urgent research target probably developed with liquid biopsy. In this session, we would review the current understanding of primary and secondary resistance, and try to figure out the way for personalized medicine in endocrine therapy.